Show simple item record

dc.contributor.authorEleftheriou, Despina
dc.contributor.authorMelo, Marianna
dc.contributor.authorMarks, Stephen D.
dc.contributor.authorTullus, Kjell
dc.contributor.authorSills, John
dc.contributor.authorCleary, Gavin
dc.contributor.authorDolezalova, Pavla
dc.contributor.authorOzen, Seza
dc.contributor.authorPilkington, Clarissa
dc.contributor.authorWoo, Pat
dc.contributor.authorKlein, Nigel
dc.contributor.authorDillon, Michael J.
dc.contributor.authorBrogan, Paul A.
dc.date.accessioned2019-12-10T10:34:53Z
dc.date.available2019-12-10T10:34:53Z
dc.date.issued2009
dc.identifier.issn1462-0324
dc.identifier.urihttps://doi.org/10.1093/rheumatology/kep148
dc.identifier.urihttp://hdl.handle.net/11655/13807
dc.description.abstractMethods. This was a retrospective descriptive case series of children with PSV treated with biologic therapy between February 2002 and November 2007. Primary retrospective outcome assessment measures were: daily corticosteroid dose; Birmingham Vasculitis Activity Score (BVAS); and adverse events (including infection rate). Results. Twenty-five patients median age 8.8 (range 2.416) years; 11 male with active PSV (n 6 with anti-neutrophil cytoplasmic antibody associated vasculitides, n 11 with polyarteritis nodosa, n 7 with unclassified vasculitis and n 1 with Behets disease) were treated with biologic agents including infliximab (n 7), rituximab (n 6), etanercept (n 4), adalimumab (n 1) or multiple biologics sequentially (n 7). Overall, there was a significant reduction in BVAS from a median of 8.5 (range 532) at start of therapy to 4 (range 019) at median 32 months follow-up (P 0.003) accompanied by significant reduction in median daily prednisolone requirement from 1 (range 0.22) to 0.25 (range 01) mg/kg/day, P 0.000. For those receiving multiple biologic agents sequentially, a similar clinical improvement was observed with corticosteroid sparing. Infections occurred in 24, the most severe in those receiving infliximab. Conclusion. Our data provide retrospective evidence of efficacy of these agents, and highlight the associated infectious complications. Further multicentre standardization of treatment protocols and data collection to inform clinical trials of biologic therapy in systemic vasculitis of the young is required.
dc.language.isoen
dc.publisherOxford Univ Press
dc.relation.isversionof10.1093/rheumatology/kep148
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectRheumatology
dc.titleBiologic Therapy in Primary Systemic Vasculitis of the Young
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalRheumatology
dc.contributor.departmentÇocuk Sağlığı ve Hastalıkları
dc.identifier.volume48
dc.identifier.issue8
dc.identifier.startpage978
dc.identifier.endpage986
dc.description.indexWoS
dc.description.indexScopus


Files in this item

This item appears in the following Collection(s)

Show simple item record